Status:
UNKNOWN
Neuropsychiatry and Cognition in SCA3/MJD
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
Spinocerebellar Ataxia Type 3
Machado-Joseph Disease
Eligibility:
All Genders
18+ years
Brief Summary
This research investigates how cognitive-affective aspects evolve during the course of SCA3/MJD. Due to COVID-19 pandemics, this study protocol was adapted for online-only consultations. Evaluations h...
Detailed Description
By the end of this study, the evaluated population will be composed of 144 participants: 36 ataxic SCA3/MJD carriers, 72 at 50% risk of carrying the SCA3/MJD mutation and 36 healthy controls. Ataxic s...
Eligibility Criteria
Inclusion
- Symptomatic:
- older than 18 year old;
- molecular diagnosis of SCA3/MJD;
- SARA\>2.5.
- At 50% risk:
- older than 18 year old;
- have a parent with molecular diagnosis of SCA3/MJD;
- SARA\<3.
- Healthy Controls
- older than 18 year old;
- no genetic relationship with a SCA3/MJD carrier.
Exclusion
- Non agreement in signing the informed consent;
- Healthy Controls: having any history of genetic disorders in their families or any psychiatric or neurologic disorder.
Key Trial Info
Start Date :
December 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT04714307
Start Date
December 13 2019
End Date
August 1 2023
Last Update
January 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903